Please login to the form below

Not currently logged in
Email:
Password:

tofacitinib

This page shows the latest tofacitinib news and features for those working in and with pharma, biotech and healthcare.

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

The results from the post-market study showed that there was an increased risk of serious heart-related problems and cancer associated with Xeljanz (tofacitinib) when compared to TNF inhibitors like

Latest news

More from news
Approximately 9 fully matching, plus 70 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....